bioAffinity Technologies (BIAF) Gross Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has 4 years of Gross Margin data on file, last reported at 43.49% in Q4 2025.

• Gross Margin for Q4 2025 came in at 43.49%, up 1425.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 31.4% (down 468.0% YoY), and the FY2025 annual result was 31.4%, down 468.0% from the prior year.
• Gross Margin rose to 43.49% in Q4 2025 per BIAF's latest filing, from 34.84% in the prior quarter.
• Over five years, Gross Margin peaked at 93.75% in Q2 2023 and troughed at 19.92% in Q2 2025.
• A 4-year average of 54.74% and a median of 41.29% in 2024 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2023 and 2025: Gross Margin tumbled 6776 bps in 2023, then jumped 1425 bps in 2025.
• A 4-year view of Gross Margin shows it stood at 92.54% in 2022, then slumped by 73 bps to 24.78% in 2023, then climbed by 18 bps to 29.24% in 2024, then surged by 49 bps to 43.49% in 2025.
• Business Quant data shows BIAF's Gross Margin at 43.49% in Q4 2025, 34.84% in Q3 2025, and 19.92% in Q2 2025.